Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL: Oral MDV3100 in Chemotherapy-Naive Metastatic Prostate Cancer After Androgen Deprivation Therapy Failure
KCT0000302Phase 3Active, not recruiting
- Sponsor
- Medivation
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Medivation. Started Nov 2011; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on KCT0000302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000302.